Photo of Matthew Hiram Taylor, M.D.

Matthew Hiram Taylor M.D.

Dr. Taylor runs the phase I clinical trials program for adults with advanced solid tumor malignancies. He also specializes in treating patients with metastatic melanoma and thyroid cancer.

Education

  • M.D., Oregon Health & Science University, Portland Oregon 2005
  • Residency:

    • Internal medicine, University of Washington, 2007
  • Fellowship:

    • Hematology and medical oncology, Oregon Health & Science University, 2010
  • Certifications:

    • American Board of Internal Medicine, 2009

Memberships and associations

  • American College of Physicians

Publications

  • "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma" New England Journal of Medicine May 21 2015
  • "Medical Therapy for Advanced Forms of Thyroid Cancer" Surgical Clinics of North America  2014
  • "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer" New England Journal of Medicine February 12 2015
  • "The ploidy conveyor of mature hepatocytes as a source of genetic variation" Nature October 7 2010
  • "Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers" Gastroenterology September 1 2015
  • "Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032)" The Lancet Oncology  2016
  • "Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer" Cancer Management and Research May 30 2016
  • "Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors" Cancer August 15 2016
  • "Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer" Journal of Clinical Endocrinology and Metabolism November 1 2016
  • "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma" The Lancet Oncology November 1 2016
  • "Academic cancer center phase i program development" Oncologist April 1 2017
  • "Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors" Journal of Clinical Oncology June 20 2017
  • "Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor)" The Lancet Oncology January 1 2018
  • "Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC)" American Journal of Hematology January 1 2018
  • "Safety profile of avelumab in patients with advanced solid tumors" Cancer January 1 2018
  • "Signature program" Oncotarget April 20 2018
  • "Defining Radioiodine-Refractory Differentiated Thyroid Cancer" Thyroid September 1 2017
  • "Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children" New England Journal of Medicine February 22 2018
  • "Precision targeted therapy with BLU-667 for RET-driven cancers" Cancer Discovery July 1 2018
  • "Concurrent Radiosurgery and Immune Checkpoint Inhibition" American Journal of Clinical Oncology January 1 2018
  • "Efficacy and Safety of Avelumab Treatment in Patients with Advanced Unresectable Mesothelioma" JAMA oncology January 1 2018
  • "Avelumab in patients with previously treated metastatic melanoma" Journal for ImmunoTherapy of Cancer January 16 2019
  • "Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer" JAMA oncology January 1 2019
  • "Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer" The Lancet Oncology May 1 2019
  • "Larotrectinib in adult patients with solid tumours" Annals of Oncology February 1 2019
  • "Correction" Journal for ImmunoTherapy of Cancer February 13 2019

Additional information

Edit profile